Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands |
| NDC | 82009-032-10 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10 |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Distribution | NJ, AZ, IN |
| Quantity | 1,856 bottles |
| Recall initiated | 2025-07-25 |
| Report date | 2025-08-20 |
| Recall completed | — |
| Recall number | D-0580-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berkeley Heights NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗